Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 197,486 | 335,639 | 298,190 | 433,584 | 122,577 |
| Marketable Securities | 568,034 | 477,777 | 365,088 | 321,646 | 404,481 |
| Receivables | 27,762 | 23,366 | 154,877 | 32,844 | 23,121 |
| Inventories | 14,457 | 11,061 | 11,375 | 11,546 | 14,138 |
| TOTAL | $872,003 | $906,039 | $894,318 | $851,017 | $613,486 |
| Non-Current Assets | |||||
| PPE Net | 48,773 | 48,339 | 47,596 | 44,348 | 31,877 |
| Investments And Advances | 129,320 | 144,288 | 77,131 | 32,926 | 26,333 |
| Intangibles | 175,600 | 175,681 | 173,406 | 173,406 | 173,426 |
| Other Non-Current Assets | 42,689 | 39,694 | 40,689 | 33,799 | 34,822 |
| TOTAL | $396,382 | $408,002 | $338,822 | $284,479 | $266,458 |
| Total Assets | $1,268,385 | $1,314,041 | $1,233,140 | $1,135,496 | $879,944 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 10,850 | 9,014 | 14,405 | 12,871 | 13,460 |
| Accrued Expenses | 79,653 | 71,887 | 67,719 | 83,194 | 69,557 |
| Other current liabilities | 102,898 | 131,570 | 107,247 | N/A | N/A |
| TOTAL | $201,186 | $219,729 | $196,858 | $103,300 | $90,307 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 367,702 | 365,419 | 393,830 | 345,126 | 31,206 |
| TOTAL | $401,008 | $398,725 | $427,136 | $378,432 | $62,372 |
| Total Liabilities | $602,194 | $618,454 | $623,994 | $481,732 | $152,679 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 61,045 | 60,590 | 59,749 | 57,889 | 57,771 |
| Common Shares | 61 | 60 | 59 | 58 | 58 |
| Retained earnings | -1,595,565 | -1,526,720 | -1,552,035 | -1,433,010 | -1,339,205 |
| Other shareholders' equity | 1,013 | 1,284 | -1,545 | -147 | -71 |
| TOTAL | $666,191 | $695,587 | $609,146 | $653,764 | $727,265 |
| Total Liabilities And Equity | $1,268,385 | $1,314,041 | $1,233,140 | $1,135,496 | $879,944 |